Minoxidil
updated
What is Minoxidil?
Minoxidil is a small molecule, not a peptide. Topical solution or foam for scalp hair loss and oral tablets for severe hypertension are different products with different approved uses, exposure, and risk.
Topical minoxidil has randomized evidence and FDA-labeled products for pattern hair loss. Oral minoxidil is an FDA-labeled severe-hypertension drug; using the tablet for hair loss is off-label and carries systemic cardiovascular risks that a topical label does not.
small-molecule vasodilator
- Small molecule, not a peptide
- Topical products have hair-loss indications
- Oral hair-loss use is off-label
- Benefit generally requires continued use
What exactly is minoxidil?
Minoxidil is a small molecule, not a peptide. Topical solution or foam for scalp hair loss and oral tablets for severe hypertension are different products with different approved uses, exposure, and risk.
DailyMed · women’s 5% foam label
US over-the-counter drug label
DailyMed, label updated 18 November 2025.
The label directs once-daily use on the top of the scalp for female pattern hair loss, describes the time needed before judging response, and says continued use is necessary to keep regrowth. It lists scalp irritation and unwanted facial hair among possible effects and includes cardiovascular warning signs that require stopping and medical review.
- Participants / model
- Women with hereditary thinning on the top of the scalp
- Treatment
- 5% topical foam once daily as labeled
- Study design
- FDA-regulated OTC labeling
FDA label · severe hypertension
FDA prescribing information
US Food and Drug Administration, Loniten prescribing information.
Oral minoxidil is labeled for severe hypertension that is symptomatic or causing target-organ damage and is not manageable with other drugs. The boxed warning describes pericardial effusion that can progress to tamponade and worsening angina; the label pairs treatment with a beta blocker and diuretic because of reflex tachycardia and fluid retention.
- Participants / model
- People with severe refractory hypertension
- Treatment
- Oral minoxidil tablets in a monitored antihypertensive regimen
- Study design
- FDA prescribing information
This label does not approve oral minoxidil for hair loss.
Read the original sourceDoes topical minoxidil regrow hair?
It can improve hair counts and scalp coverage in androgenetic alopecia, but response varies and the evidence applies to pattern hair loss rather than every cause of shedding. In a 393-man trial, 5% solution outperformed 2% and vehicle over 48 weeks.
The trial’s “45% more regrowth” language is a relative comparison between the 5% and 2% groups, not the percentage of users who regrew hair.
48-week RCT · 5%, 2%, and vehicle
Randomized double-blind trial
Olsen EA et al. Journal of the American Academy of Dermatology, 2002.
393 men were randomized to 5% solution, 2% solution, or vehicle twice daily for 48 weeks. Five percent improved hair-count and assessment outcomes more than the other arms, but also caused more pruritus and local irritation. The paper’s 45% figure is a relative comparison with 2%, not a 45-percentage-point response rate.
- Participants / model
- 393 men aged 18 to 49 with androgenetic alopecia
- Treatment
- 5% topical solution, 2% solution, or vehicle twice daily
- Follow-up
- 48 weeks
- Study design
- Multicenter randomized double-blind vehicle-controlled trial
DailyMed · women’s 5% foam label
US over-the-counter drug label
DailyMed, label updated 18 November 2025.
The label directs once-daily use on the top of the scalp for female pattern hair loss, describes the time needed before judging response, and says continued use is necessary to keep regrowth. It lists scalp irritation and unwanted facial hair among possible effects and includes cardiovascular warning signs that require stopping and medical review.
- Participants / model
- Women with hereditary thinning on the top of the scalp
- Treatment
- 5% topical foam once daily as labeled
- Study design
- FDA-regulated OTC labeling
DailyMed · men’s topical label
US over-the-counter drug label
DailyMed prescribing information.
Men’s topical labels cover hereditary hair loss on the top of the scalp, require continued use to maintain regrowth, and warn against use for sudden, patchy, unexplained, or inflamed-scalp hair loss.
- Participants / model
- Men with hereditary thinning on the top of the scalp
- Treatment
- Topical minoxidil according to the product-specific label
- Study design
- FDA-regulated OTC labeling
How does it affect a hair follicle?
Follicles convert minoxidil to minoxidil sulfate, and laboratory work implicates potassium-channel, vascular, growth-factor, and hair-cycle effects. The complete clinical mechanism is still not settled, and mechanism does not predict an individual response.
Mechanism review · sulfation and follicles
Pharmacology review
Messenger AG, Rundegren J. British Journal of Dermatology, 2004.
The review describes conversion to minoxidil sulfate by follicular sulfotransferase and several plausible follicular actions, while concluding that the complete mechanism of hair growth remains unresolved.
- Study design
- Narrative pharmacology review
What happens after minoxidil is stopped?
The labeled benefit requires continued use. New growth is generally lost after treatment stops, so a short course is not expected to permanently reset pattern hair loss.
Is early shedding proof that it is working?
No. Hair-cycle shifts can cause early shedding, but sudden, patchy, severe, or otherwise unexplained loss may have another cause. The product labels exclude several of those scenarios rather than treating shedding as a universal success marker.
DailyMed · women’s 5% foam label
US over-the-counter drug label
DailyMed, label updated 18 November 2025.
The label directs once-daily use on the top of the scalp for female pattern hair loss, describes the time needed before judging response, and says continued use is necessary to keep regrowth. It lists scalp irritation and unwanted facial hair among possible effects and includes cardiovascular warning signs that require stopping and medical review.
- Participants / model
- Women with hereditary thinning on the top of the scalp
- Treatment
- 5% topical foam once daily as labeled
- Study design
- FDA-regulated OTC labeling
DailyMed · men’s topical label
US over-the-counter drug label
DailyMed prescribing information.
Men’s topical labels cover hereditary hair loss on the top of the scalp, require continued use to maintain regrowth, and warn against use for sudden, patchy, unexplained, or inflamed-scalp hair loss.
- Participants / model
- Men with hereditary thinning on the top of the scalp
- Treatment
- Topical minoxidil according to the product-specific label
- Study design
- FDA-regulated OTC labeling
DailyMed · women’s 5% foam label
US over-the-counter drug label
DailyMed, label updated 18 November 2025.
The label directs once-daily use on the top of the scalp for female pattern hair loss, describes the time needed before judging response, and says continued use is necessary to keep regrowth. It lists scalp irritation and unwanted facial hair among possible effects and includes cardiovascular warning signs that require stopping and medical review.
- Participants / model
- Women with hereditary thinning on the top of the scalp
- Treatment
- 5% topical foam once daily as labeled
- Study design
- FDA-regulated OTC labeling
DailyMed · men’s topical label
US over-the-counter drug label
DailyMed prescribing information.
Men’s topical labels cover hereditary hair loss on the top of the scalp, require continued use to maintain regrowth, and warn against use for sudden, patchy, unexplained, or inflamed-scalp hair loss.
- Participants / model
- Men with hereditary thinning on the top of the scalp
- Treatment
- Topical minoxidil according to the product-specific label
- Study design
- FDA-regulated OTC labeling
Is low-dose oral minoxidil better than topical minoxidil?
The 24-week trial did not show oral 5 mg to be superior on its primary density comparisons. Oral hair use remains off-label, and the tablet exposes the whole body to a drug whose approved label addresses severe hypertension.
| Outcome | Between-group estimate |
|---|---|
| Frontal terminal density | 3.1 hairs/cm², 95% CI -18.2 to 21.5, P=.27 |
| Vertex terminal density | 23.4 hairs/cm², 95% CI -0.3 to 43.0, P=.09 |
| Oral-arm hypertrichosis | 22 of 45 assigned participants |
24-week RCT · oral not superior
Randomized double-dummy trial
Penha MA et al. JAMA Dermatology, 2024.
Ninety men enrolled and 68 completed. Daily oral 5 mg did not show superiority to twice-daily topical 5% for the primary frontal and vertex hair-density comparisons. Hypertrichosis occurred in 22 of 45 assigned oral treatment and headache in 6 of 45.
- Participants / model
- 90 randomized men with androgenetic alopecia; 68 completers
- Treatment
- Oral 5 mg daily or topical 5% twice daily, each with matched placebo
- Follow-up
- 24 weeks
- Study design
- Single-center randomized double-blind double-dummy trial
- Funding
- Brazilian Dermatology Society support disclosed
The trial tested one oral regimen in men and was not powered to define rare cardiovascular risk.
Read the original sourceFDA label · severe hypertension
FDA prescribing information
US Food and Drug Administration, Loniten prescribing information.
Oral minoxidil is labeled for severe hypertension that is symptomatic or causing target-organ damage and is not manageable with other drugs. The boxed warning describes pericardial effusion that can progress to tamponade and worsening angina; the label pairs treatment with a beta blocker and diuretic because of reflex tachycardia and fluid retention.
- Participants / model
- People with severe refractory hypertension
- Treatment
- Oral minoxidil tablets in a monitored antihypertensive regimen
- Study design
- FDA prescribing information
This label does not approve oral minoxidil for hair loss.
Read the original sourceWhat risks matter most?
Topical products commonly cause local irritation and can cause unwanted hair growth. Oral exposure adds systemic risks including fluid retention, faster heart rate, worsening angina, and pericardial effusion; rare-risk estimates cannot be taken from a small hair trial.
- Topical: scalp irritation, itching, unwanted facial hair, and product-specific excipient reactions.
- Oral: hypertrichosis is common in hair studies; edema, tachycardia, blood-pressure effects, angina, and pericardial disease are the higher-consequence concerns.
- Wrong diagnosis: sudden, patchy, postpartum, medication-related, inflammatory, or scarring hair loss is outside the ordinary OTC pattern-hair-loss label.
48-week RCT · 5%, 2%, and vehicle
Randomized double-blind trial
Olsen EA et al. Journal of the American Academy of Dermatology, 2002.
393 men were randomized to 5% solution, 2% solution, or vehicle twice daily for 48 weeks. Five percent improved hair-count and assessment outcomes more than the other arms, but also caused more pruritus and local irritation. The paper’s 45% figure is a relative comparison with 2%, not a 45-percentage-point response rate.
- Participants / model
- 393 men aged 18 to 49 with androgenetic alopecia
- Treatment
- 5% topical solution, 2% solution, or vehicle twice daily
- Follow-up
- 48 weeks
- Study design
- Multicenter randomized double-blind vehicle-controlled trial
24-week RCT · oral not superior
Randomized double-dummy trial
Penha MA et al. JAMA Dermatology, 2024.
Ninety men enrolled and 68 completed. Daily oral 5 mg did not show superiority to twice-daily topical 5% for the primary frontal and vertex hair-density comparisons. Hypertrichosis occurred in 22 of 45 assigned oral treatment and headache in 6 of 45.
- Participants / model
- 90 randomized men with androgenetic alopecia; 68 completers
- Treatment
- Oral 5 mg daily or topical 5% twice daily, each with matched placebo
- Follow-up
- 24 weeks
- Study design
- Single-center randomized double-blind double-dummy trial
- Funding
- Brazilian Dermatology Society support disclosed
The trial tested one oral regimen in men and was not powered to define rare cardiovascular risk.
Read the original sourceFDA label · severe hypertension
FDA prescribing information
US Food and Drug Administration, Loniten prescribing information.
Oral minoxidil is labeled for severe hypertension that is symptomatic or causing target-organ damage and is not manageable with other drugs. The boxed warning describes pericardial effusion that can progress to tamponade and worsening angina; the label pairs treatment with a beta blocker and diuretic because of reflex tachycardia and fluid retention.
- Participants / model
- People with severe refractory hypertension
- Treatment
- Oral minoxidil tablets in a monitored antihypertensive regimen
- Study design
- FDA prescribing information
This label does not approve oral minoxidil for hair loss.
Read the original sourceWhich uses are actually approved?
US topical minoxidil products have OTC labeling for specified pattern hair loss. Oral minoxidil is approved for severe refractory hypertension, not hair loss.
DailyMed · women’s 5% foam label
US over-the-counter drug label
DailyMed, label updated 18 November 2025.
The label directs once-daily use on the top of the scalp for female pattern hair loss, describes the time needed before judging response, and says continued use is necessary to keep regrowth. It lists scalp irritation and unwanted facial hair among possible effects and includes cardiovascular warning signs that require stopping and medical review.
- Participants / model
- Women with hereditary thinning on the top of the scalp
- Treatment
- 5% topical foam once daily as labeled
- Study design
- FDA-regulated OTC labeling
DailyMed · men’s topical label
US over-the-counter drug label
DailyMed prescribing information.
Men’s topical labels cover hereditary hair loss on the top of the scalp, require continued use to maintain regrowth, and warn against use for sudden, patchy, unexplained, or inflamed-scalp hair loss.
- Participants / model
- Men with hereditary thinning on the top of the scalp
- Treatment
- Topical minoxidil according to the product-specific label
- Study design
- FDA-regulated OTC labeling
FDA label · severe hypertension
FDA prescribing information
US Food and Drug Administration, Loniten prescribing information.
Oral minoxidil is labeled for severe hypertension that is symptomatic or causing target-organ damage and is not manageable with other drugs. The boxed warning describes pericardial effusion that can progress to tamponade and worsening angina; the label pairs treatment with a beta blocker and diuretic because of reflex tachycardia and fluid retention.
- Participants / model
- People with severe refractory hypertension
- Treatment
- Oral minoxidil tablets in a monitored antihypertensive regimen
- Study design
- FDA prescribing information
This label does not approve oral minoxidil for hair loss.
Read the original sourceStudies and sources
48-week RCT · 5%, 2%, and vehicle
Randomized double-blind trial
Olsen EA et al. Journal of the American Academy of Dermatology, 2002.
393 men were randomized to 5% solution, 2% solution, or vehicle twice daily for 48 weeks. Five percent improved hair-count and assessment outcomes more than the other arms, but also caused more pruritus and local irritation. The paper’s 45% figure is a relative comparison with 2%, not a 45-percentage-point response rate.
- Participants / model
- 393 men aged 18 to 49 with androgenetic alopecia
- Treatment
- 5% topical solution, 2% solution, or vehicle twice daily
- Follow-up
- 48 weeks
- Study design
- Multicenter randomized double-blind vehicle-controlled trial
24-week RCT · oral not superior
Randomized double-dummy trial
Penha MA et al. JAMA Dermatology, 2024.
Ninety men enrolled and 68 completed. Daily oral 5 mg did not show superiority to twice-daily topical 5% for the primary frontal and vertex hair-density comparisons. Hypertrichosis occurred in 22 of 45 assigned oral treatment and headache in 6 of 45.
- Participants / model
- 90 randomized men with androgenetic alopecia; 68 completers
- Treatment
- Oral 5 mg daily or topical 5% twice daily, each with matched placebo
- Follow-up
- 24 weeks
- Study design
- Single-center randomized double-blind double-dummy trial
- Funding
- Brazilian Dermatology Society support disclosed
The trial tested one oral regimen in men and was not powered to define rare cardiovascular risk.
Read the original sourceDailyMed · women’s 5% foam label
US over-the-counter drug label
DailyMed, label updated 18 November 2025.
The label directs once-daily use on the top of the scalp for female pattern hair loss, describes the time needed before judging response, and says continued use is necessary to keep regrowth. It lists scalp irritation and unwanted facial hair among possible effects and includes cardiovascular warning signs that require stopping and medical review.
- Participants / model
- Women with hereditary thinning on the top of the scalp
- Treatment
- 5% topical foam once daily as labeled
- Study design
- FDA-regulated OTC labeling
DailyMed · men’s topical label
US over-the-counter drug label
DailyMed prescribing information.
Men’s topical labels cover hereditary hair loss on the top of the scalp, require continued use to maintain regrowth, and warn against use for sudden, patchy, unexplained, or inflamed-scalp hair loss.
- Participants / model
- Men with hereditary thinning on the top of the scalp
- Treatment
- Topical minoxidil according to the product-specific label
- Study design
- FDA-regulated OTC labeling
FDA label · severe hypertension
FDA prescribing information
US Food and Drug Administration, Loniten prescribing information.
Oral minoxidil is labeled for severe hypertension that is symptomatic or causing target-organ damage and is not manageable with other drugs. The boxed warning describes pericardial effusion that can progress to tamponade and worsening angina; the label pairs treatment with a beta blocker and diuretic because of reflex tachycardia and fluid retention.
- Participants / model
- People with severe refractory hypertension
- Treatment
- Oral minoxidil tablets in a monitored antihypertensive regimen
- Study design
- FDA prescribing information
This label does not approve oral minoxidil for hair loss.
Read the original sourceMechanism review · sulfation and follicles
Pharmacology review
Messenger AG, Rundegren J. British Journal of Dermatology, 2004.
The review describes conversion to minoxidil sulfate by follicular sulfotransferase and several plausible follicular actions, while concluding that the complete mechanism of hair growth remains unresolved.
- Study design
- Narrative pharmacology review
Why is Minoxidil in S tier?
S tier comes from mature randomized evidence and FDA-labeled topical products for pattern hair loss. Oral hair use remains off-label, and neither route treats every cause of hair loss.
read Minoxidil in the reptides guide, chapter 19: 9 pages, free to read.